Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass (Q44781832)
Jump to navigation
Jump to search
scientific article published in March 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass |
scientific article published in March 2004 |
Statements
1 reference
Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass (English)
1 reference
Stanton K Shernan
1 reference
Jane C K Fitch
1 reference
Nancy A Nussmeier
1 reference
John C Chen
1 reference
Scott A Rollins
1 reference
Christopher F Mojcik
1 reference
Kevin J Malloy
1 reference
Thomas G Todaro
1 reference
Thomas Filloon
1 reference
Steven W Boyce
1 reference
Deepak M Gangahar
1 reference
Michael Goldberg
1 reference
Lawrence J Saidman
1 reference
Dennis T Mangano
1 reference
Pexelizumab Study Investigators
1 reference
1 March 2004
1 reference
1 reference
Identifiers
1 reference